The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event-Reference-Cited by-同舟云学术

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event

Published:2020-09-19 Issue:12 Volume:95 Page:1562-1571
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Locher Maurus¹^ORCID,Steurer Michael²,Jukic Emina¹,Keller Markus A.¹,Fresser Friedrich¹,Ruepp Carmen³,Wöll Ewald³,Verdorfer Irmgard¹,Gastl Günther²,Willenbacher Wolfgang²⁴,Weger Roman⁴,Nachbaur David²,Wolf Dominik²⁵,Gunsilius Eberhard²,Zschocke Johannes¹,Steiner Normann²^ORCID

Affiliation:

1. Institute of Human Genetics Medical University of Innsbruck Innsbruck Austria

2. Department of Internal Medicine V Medical University of Innsbruck Innsbruck Austria

3. Department of Internal Medicine St. Vinzenz Krankenhaus Betriebs GmbH Zams Austria

4. ONCOTYROL ‐ Center for Personalized Cancer Medicine Innsbruck Austria

5. Medical Clinic 3, Oncology, Hematology, Immuno‐Oncology and Rheumatology University Hospital Bonn Bonn Germany

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25994

Reference40 articles.

1. IMWG consensus on risk stratification in multiple myeloma

2. Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

3. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability

4. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

5. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease;Blood Cancer Journal;2024-08-26

2. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells;Blood Cancer Journal;2024-06-07

3. Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review;Medicine;2024-04-05

4. Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors;2023-08-03

5. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities;Leukemia & Lymphoma;2023-06-10